Odds of mortality or discharge to hospice reduced for those receiving supplemental oxygen or mechanical ventilation and/or ECMO
Your search for supplemental oxygen returned 19 results
Current evidence indicates that a 6mg dose of dexamethasone daily is effective for improving COVID-19 outcomes among patients receiving supplemental oxygen.
No significant difference versus placebo observed for hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen
InflaRx is working to increase supply of the product in the US as quickly as possible.
Significant reductions seen in RSV-related infections, RSV-related hospitalizations for three monoclonal antibodies versus placebo
Methods to prevent and treat COVID-19 in cancer patients have had to evolve alongside the SARS-CoV-2 virus.
The studies evaluated routine clinical practice data from more than 800 hospitals in the US.
While naloxone, a short-acting opioid antagonist, has become the standard treatment for opioid overdose, there are situations where longer-acting opioid antagonists are a more appropriate treatment choice, especially considering the rise of fentanyl. In this article, Dr Adam Bisaga, professor of psychiatry at the Columbia University Irving Medical Center in New York and research scientist at the New York State Psychiatric Institute, discusses various clinical considerations in the treatment of opioid overdose and opioid use disorder.
Actemra (tocilizumab) is an interleukin-6 receptor antagonist.
Kineret is an interleukin-1 receptor antagonist.